Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Annual Meeting of Stockholders
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • COVID-19
  • Our Team
    • Management Team
    • Board of Directors
  • Publications
  • Scientific Advisory Board
  • Newsroom
  • Investors
  • Contact
Latest News

IMPORTANT CORRECTION OF INVESTIGATIONAL DRUG INFORMATION

On February 11, 2022, CytoDyn, Inc. received a Warning Letter from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion in which FDA asserted that statements made in a video created a misleading impression regarding the safety and efficacy of leronlimab.  Leronlimab is an investigational drug that has not been approved (or authorized) by the U.S. FDA for the treatment of COVID-19 or for any indication.  For more information, click here to access a Dear Healthcare Provider (DHCP) Letter: View Here.

Publications

Antimicrobial Agents and Chemotherapy: Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

Antimicrobial Agents and Chemotherapy: Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

Jul 20, 2010
RSS
  • « Previous
  • 1
  • 2
© 2022 CytoDyn Inc. All Rights Reserved.
  • Twitter
  • Facebookj
Privacy Policy Disclaimer Sitemap